A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the low-density lipoprotein cholesterol
(LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg
versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in
Japanese patients with hypercholesterolemia treated for 12 weeks.